Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy.

Bender, Jonathan D; Rubinstein, Jeremy D; Mizukawa, Benjamin; Perentesis, John P; Pommert, Lauren

Bender, Jonathan D; Rubinstein, Jeremy D; Mizukawa, Benjamin; Perentesis, John P; Pommert, Lauren.

Afiliación

Bender JD; Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Rubinstein JD; Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Mizukawa B; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Perentesis JP; Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Pommert L; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Pediatr Blood Cancer ; 70(4): e30214, 2023 04.

Article en En | MEDLINE | ID: mdl-36694431

Asunto(s)

Gemcitabina; Linfoma no Hodgkin; Adulto; Humanos; Niño; Adolescente; Anciano; Rituximab; Oxaliplatino; Estudios Retrospectivos; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Linfoma no Hodgkin/tratamiento farmacológico; Desoxicitidina; Resultado del Tratamiento

Palabras clave

comorbidities; medically unfit; pediatric non-Hodgkin lymphoma

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Gemcitabina Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Humans Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google